Research ExplorerPublicationsReduced-intensity transplantation for lymphomas using haploi...

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

Standard

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. / Kanate, Abraham S; Mussetti, Alberto; Kharfan-Dabaja, Mohamed A; Ahn, Kwang W; DiGilio, Alyssa; Beitinjaneh, Amer; Chhabra, Saurabh; Fenske, Timothy S; Freytes, Cesar; Gale, Robert Peter; Ganguly, Siddhartha; Hertzberg, Mark; Klyuchnikov, Evgeny; Lazarus, Hillard M; Olsson, Richard; Perales, Miguel-Angel; Rezvani, Andrew; Riches, Marcie; Saad, Ayman; Slavin, Shimon; Smith, Sonali M; Sureda, Anna; Yared, Jean; Ciurea, Stefan; Armand, Philippe; Salit, Rachel; Bolaños-Meade, Javier; Hamadani, Mehdi.

In: BLOOD, Vol. 127, No. 7, 18.02.2016, p. 938-47.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kanate, AS, Mussetti, A, Kharfan-Dabaja, MA, Ahn, KW, DiGilio, A, Beitinjaneh, A, Chhabra, S, Fenske, TS, Freytes, C, Gale, RP, Ganguly, S, Hertzberg, M, Klyuchnikov, E, Lazarus, HM, Olsson, R, Perales, M-A, Rezvani, A, Riches, M, Saad, A, Slavin, S, Smith, SM, Sureda, A, Yared, J, Ciurea, S, Armand, P, Salit, R, Bolaños-Meade, J & Hamadani, M 2016, 'Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors', BLOOD, vol. 127, no. 7, pp. 938-47. https://doi.org/10.1182/blood-2015-09-671834

APA

Kanate, A. S., Mussetti, A., Kharfan-Dabaja, M. A., Ahn, K. W., DiGilio, A., Beitinjaneh, A., Chhabra, S., Fenske, T. S., Freytes, C., Gale, R. P., Ganguly, S., Hertzberg, M., Klyuchnikov, E., Lazarus, H. M., Olsson, R., Perales, M-A., Rezvani, A., Riches, M., Saad, A., ... Hamadani, M. (2016). Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. BLOOD, 127(7), 938-47. https://doi.org/10.1182/blood-2015-09-671834

Vancouver

Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. BLOOD. 2016 Feb 18;127(7):938-47. https://doi.org/10.1182/blood-2015-09-671834

Bibtex

@article{a190bc7f9df242f99053a51a392c5887,
title = "Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors",
abstract = "We evaluated 917 adult lymphoma patients who received haploidentical (n = 185) or HLA-matched unrelated donor (URD) transplantation either with (n = 241) or without antithymocyte globulin (ATG; n = 491) following reduced-intensity conditioning regimens. Haploidentical recipients received posttransplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, whereas URD recipients received calcineurin inhibitor-based prophylaxis. Median follow-up of survivors was 3 years. The 100-day cumulative incidence of grade III-IV acute GVHD on univariate analysis was 8%, 12%, and 17% in the haploidentical, URD without ATG, and URD with ATG groups, respectively (P = .44). Corresponding 1-year rates of chronic GVHD on univariate analysis were 13%, 51%, and 33%, respectively (P < .001). On multivariate analysis, grade III-IV acute GVHD was higher in URD without ATG (P = .001), as well as URD with ATG (P = .01), relative to haploidentical transplants. Similarly, relative to haploidentical transplants, risk of chronic GVHD was higher in URD without ATG and URD with ATG (P < .0001). Cumulative incidence of relapse/progression at 3 years was 36%, 28%, and 36% in the haploidentical, URD without ATG, and URD with ATG groups, respectively (P = .07). Corresponding 3-year overall survival (OS) was 60%, 62%, and 50% in the 3 groups, respectively, with multivariate analysis showing no survival difference between URD without ATG (P = .21) or URD with ATG (P = .16), relative to haploidentical transplants. Multivariate analysis showed no difference between the 3 groups in terms of nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). These data suggest that reduced-intensity conditioning haploidentical transplantation with posttransplant cyclophosphamide does not compromise early survival outcomes compared with matched URD transplantation, and is associated with significantly reduced risk of chronic GVHD.",
author = "Kanate, {Abraham S} and Alberto Mussetti and Kharfan-Dabaja, {Mohamed A} and Ahn, {Kwang W} and Alyssa DiGilio and Amer Beitinjaneh and Saurabh Chhabra and Fenske, {Timothy S} and Cesar Freytes and Gale, {Robert Peter} and Siddhartha Ganguly and Mark Hertzberg and Evgeny Klyuchnikov and Lazarus, {Hillard M} and Richard Olsson and Miguel-Angel Perales and Andrew Rezvani and Marcie Riches and Ayman Saad and Shimon Slavin and Smith, {Sonali M} and Anna Sureda and Jean Yared and Stefan Ciurea and Philippe Armand and Rachel Salit and Javier Bola{\~n}os-Meade and Mehdi Hamadani",
note = "{\textcopyright} 2016 by The American Society of Hematology.",
year = "2016",
month = feb,
day = "18",
doi = "10.1182/blood-2015-09-671834",
language = "English",
volume = "127",
pages = "938--47",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

RIS

TY - JOUR

T1 - Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

AU - Kanate, Abraham S

AU - Mussetti, Alberto

AU - Kharfan-Dabaja, Mohamed A

AU - Ahn, Kwang W

AU - DiGilio, Alyssa

AU - Beitinjaneh, Amer

AU - Chhabra, Saurabh

AU - Fenske, Timothy S

AU - Freytes, Cesar

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - Hertzberg, Mark

AU - Klyuchnikov, Evgeny

AU - Lazarus, Hillard M

AU - Olsson, Richard

AU - Perales, Miguel-Angel

AU - Rezvani, Andrew

AU - Riches, Marcie

AU - Saad, Ayman

AU - Slavin, Shimon

AU - Smith, Sonali M

AU - Sureda, Anna

AU - Yared, Jean

AU - Ciurea, Stefan

AU - Armand, Philippe

AU - Salit, Rachel

AU - Bolaños-Meade, Javier

AU - Hamadani, Mehdi

N1 - © 2016 by The American Society of Hematology.

PY - 2016/2/18

Y1 - 2016/2/18

N2 - We evaluated 917 adult lymphoma patients who received haploidentical (n = 185) or HLA-matched unrelated donor (URD) transplantation either with (n = 241) or without antithymocyte globulin (ATG; n = 491) following reduced-intensity conditioning regimens. Haploidentical recipients received posttransplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, whereas URD recipients received calcineurin inhibitor-based prophylaxis. Median follow-up of survivors was 3 years. The 100-day cumulative incidence of grade III-IV acute GVHD on univariate analysis was 8%, 12%, and 17% in the haploidentical, URD without ATG, and URD with ATG groups, respectively (P = .44). Corresponding 1-year rates of chronic GVHD on univariate analysis were 13%, 51%, and 33%, respectively (P < .001). On multivariate analysis, grade III-IV acute GVHD was higher in URD without ATG (P = .001), as well as URD with ATG (P = .01), relative to haploidentical transplants. Similarly, relative to haploidentical transplants, risk of chronic GVHD was higher in URD without ATG and URD with ATG (P < .0001). Cumulative incidence of relapse/progression at 3 years was 36%, 28%, and 36% in the haploidentical, URD without ATG, and URD with ATG groups, respectively (P = .07). Corresponding 3-year overall survival (OS) was 60%, 62%, and 50% in the 3 groups, respectively, with multivariate analysis showing no survival difference between URD without ATG (P = .21) or URD with ATG (P = .16), relative to haploidentical transplants. Multivariate analysis showed no difference between the 3 groups in terms of nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). These data suggest that reduced-intensity conditioning haploidentical transplantation with posttransplant cyclophosphamide does not compromise early survival outcomes compared with matched URD transplantation, and is associated with significantly reduced risk of chronic GVHD.

AB - We evaluated 917 adult lymphoma patients who received haploidentical (n = 185) or HLA-matched unrelated donor (URD) transplantation either with (n = 241) or without antithymocyte globulin (ATG; n = 491) following reduced-intensity conditioning regimens. Haploidentical recipients received posttransplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, whereas URD recipients received calcineurin inhibitor-based prophylaxis. Median follow-up of survivors was 3 years. The 100-day cumulative incidence of grade III-IV acute GVHD on univariate analysis was 8%, 12%, and 17% in the haploidentical, URD without ATG, and URD with ATG groups, respectively (P = .44). Corresponding 1-year rates of chronic GVHD on univariate analysis were 13%, 51%, and 33%, respectively (P < .001). On multivariate analysis, grade III-IV acute GVHD was higher in URD without ATG (P = .001), as well as URD with ATG (P = .01), relative to haploidentical transplants. Similarly, relative to haploidentical transplants, risk of chronic GVHD was higher in URD without ATG and URD with ATG (P < .0001). Cumulative incidence of relapse/progression at 3 years was 36%, 28%, and 36% in the haploidentical, URD without ATG, and URD with ATG groups, respectively (P = .07). Corresponding 3-year overall survival (OS) was 60%, 62%, and 50% in the 3 groups, respectively, with multivariate analysis showing no survival difference between URD without ATG (P = .21) or URD with ATG (P = .16), relative to haploidentical transplants. Multivariate analysis showed no difference between the 3 groups in terms of nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). These data suggest that reduced-intensity conditioning haploidentical transplantation with posttransplant cyclophosphamide does not compromise early survival outcomes compared with matched URD transplantation, and is associated with significantly reduced risk of chronic GVHD.

U2 - 10.1182/blood-2015-09-671834

DO - 10.1182/blood-2015-09-671834

M3 - SCORING: Journal article

C2 - 26670632

VL - 127

SP - 938

EP - 947

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 7

ER -